FDA Shared Exclusivity Decision May Stem From FTC Influence – Attny Fleder
Executive Summary
FDA's decision to award "shared" exclusivity for generic Prilosec may be a signal of a subtle effect of the Federal Trade Commission on the agency, Hyman, Phelps & McNamara attorney John Fleder suggested
You may also be interested in...
“Shared” Generic Exclusivity In Multi-Patent Cases Speeds Launch – FDA
Providing shared exclusivity to generic applicants ensures faster access to market for generics, FDA said in explaining its shift from a "patent by patent" approach to 180-day exclusivity
FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition
Patents that claim any unapproved aspects of an approved drug should not be listed in the "Orange Book," the Federal Trade Commission maintained.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011